Misoprostol Administration Before Operative Hysteroscopy

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

February 28, 2014

Conditions
Endometrial Disorder
Interventions
DRUG

Oral misoprostol

Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation

DRUG

Sublingual misoprostol

Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation

DRUG

Vaginal misoprostol

Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation

DRUG

Control

The control group was not given any cervical priming agents or placebo.

Trial Locations (1)

135-081

CHA Gangnam Medical Center, Seoul

All Listed Sponsors
lead

CHA University

OTHER

NCT01805115 - Misoprostol Administration Before Operative Hysteroscopy | Biotech Hunter | Biotech Hunter